Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10446838" target="_blank" >RIV/00669806:_____/22:10446838 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/22:10446838
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=khyKqEQyp8" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=khyKqEQyp8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/diagnostics12081799" target="_blank" >10.3390/diagnostics12081799</a>
Alternative languages
Result language
angličtina
Original language name
Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
Original language description
The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the purpose of providing information about solid tumors was introduced approximately 20 years ago. Additional to the detection of circulating tumor cells (CTCs), the liquid biopsy approach quickly included the analysis of circulating tumor DNA (ctDNA) and other tumor-derived markers such as circulating cell-free RNA or extracellular vesicles. Liquid biopsy is a non-invasive technique for detecting multiple cancer-associated biomarkers that is easy to obtain and can reflect the characteristics of the entire tumor mass. Currently, ctDNA is the key component of the liquid biopsy approach from the point of view of the prognosis assessment, prediction, and monitoring of the treatment of non-small-cell lung cancer (NSCLC) patients. ctDNA in NSCLC patients carries variants or rearrangements that drive carcinogenesis, such as those in EGFR, KRAS, ALK, or ROS1. Due to advances in pharmacology, these variants are the subject of targeted therapy. Therefore, the detection of these variants has gained attention in clinical medicine. Recently, methods based on qPCR (ddPCR, BEAMing) and next-generation sequencing (NGS) are the most effective approaches for ctDNA analysis. This review addresses various aspects of the use of liquid biopsy with an emphasis on ctDNA as a biomarker in NSCLC patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30100 - Basic medicine
Result continuities
Project
<a href="/en/project/LTAUSA19080" target="_blank" >LTAUSA19080: Circulating tumor DNA and micro RNA for detection of minimal residual disease and recurrence of malignant melanoma in early stages</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diagnostics [online]
ISSN
2075-4418
e-ISSN
2075-4418
Volume of the periodical
12
Issue of the periodical within the volume
8
Country of publishing house
CH - SWITZERLAND
Number of pages
20
Pages from-to
1799
UT code for WoS article
000846157800001
EID of the result in the Scopus database
2-s2.0-85137413869